Investigating Ivermectin as a Potential Treatment for COVID-19

Overview of Drug Repurposing in the COVID-19 Pandemic

As the COVID-19 pandemic, driven by the SARS-CoV-2 virus, continues to escalate globally, researchers are actively exploring potential drug therapies. Repurposing existing medications may expedite the discovery of safe and effective treatments for COVID-19. One such candidate under investigation is ivermectin.

Understanding Ivermectin’s Antimicrobial Properties

Ivermectin is a versatile antimicrobial agent known for its anti-parasitic, anti-viral, anti-bacterial, and anti-cancer effects. Originally utilized in veterinary medicine since the early 1980s, it is also prescribed for various human diseases, including the tropical parasitic infection onchocerciasis (river blindness). Laboratory studies have suggested that ivermectin exhibits significant antiviral activity against multiple human viruses, although these effects require further validation through clinical trials.

Laboratory Findings on Ivermectin and SARS-CoV-2

Researchers in Australia have conducted laboratory tests to evaluate the antiviral properties of ivermectin against SARS-CoV-2. Their findings, published in the journal *Antiviral Research*, reveal that ivermectin successfully eradicated the virus from infected cell cultures.

The experimental procedure involved infecting cell cultures with SARS-CoV-2 and administering ivermectin two hours post-infection. Results showed that by 48 hours, the treated cultures exhibited complete eradication of the viral RNA. Dr. Kylie Wagstaff, a lead researcher from the Monash Biomedicine Discovery Unit, remarked, “We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it.”

Mechanism of Action and Future Research Directions

The precise mechanism through which ivermectin acts on SARS-CoV-2 remains uncertain. Previous studies indicate that ivermectin might inhibit the virus’s ability to suppress the host cell’s viral-clearing mechanisms.

While the initial findings are promising, researchers emphasize the necessity for clinical trials involving human participants to assess the efficacy and safety of ivermectin for COVID-19 treatment. Although generally regarded as safe, the concentrations used in laboratory settings were significantly higher than those established in approved therapeutic doses, raising concerns about potential side effects at elevated levels. Dr. Wagstaff noted, “We need to figure out now whether the dosage you can use in humans will be effective – that’s the next step.”

References

1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi:10.1016/j.antiviral.2020.104787
2. Monash University, Press release 3 Apr 2020. Possible coronavirus drug identified by Australian scientists. https://www.eurekalert.org/pub_releases/2020-04/mu-pcd040320.php
3. Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):23. Published 2020 May 30. doi:10.1186/s12941-020-00368-w
4. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020;73(9):593-602. doi:10.1038/s41429-020-0336-z.
Image by Gerd Altmann from Pixabay.